Sat, Dec 20, 2014, 3:00 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Prana Biotechnology Limited Message Board

  • asmariano3 asmariano3 Feb 6, 2014 7:50 AM Flag


    Scientific Objectives

    ◾ To expand Prana’s MPAC platform to build new pipeline assets.
    ◾ Identification of new MPACs for the treatment of AD.
    ◾ Identification of new MPACs for the treatment of other neurodegenerative diseases.
    ◾ Identification of MPACs for the treatment of selected cancers, including Brain Cancer.
    ◾ Identification of non-MPACs for the treatment of AD. Since the initiation of Prana chemistry in 2001, more than 1000 compounds now exist in the company's chemical library. Those compounds are tested in a panoply of disease-specific screens, providing structure-activity relationship (SAR) information. The information from these data sets is then critically analysed to rationally design the next set of compounds.

    Outcomes of Discovery
    ◾ Up to 2002: Screening of hundreds of potential leads through AD screens to identify the 8-hydroxyquinolines as an active scaffold.
    ◾ 2002-2003: Approximately 200 8-hydroxyquinolines were synthesized, resulting in the discovery of PBT2 (nomination as a candidate in 2003)
    ◾ 2003-present: Over 200 non-8-hydroxyquinoline Follow-Up compounds were synthesized. From this, a number of candidates for AD (PBT3 series) and other indications (PBT4 series) are being pursued.
    ◾ 2002-present: Non-MPACs projects are being pursued as therapeutic and imaging agents.

1.87-0.03(-1.58%)Dec 19 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.